ISRCTN42054893已完成1 期
Phase I/II study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma
niversity of Birmingham (UK)0 个研究点目标入组 58 人开始时间: 2013年12月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 58
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 11/06/2018:
- •1. Aged =16 years
- •2. Life expectancy > 12 weeks
- •3. ECOG performance status =2
- •4. Relapsed or refractory* peripheral Tcell lymphoma including the following histologies: peripheral Tcelllymphoma not otherwise specified, angioimmunoblastic Tcell lymphoma, anaplastic large cell lymphoma, enteropathy associated Tcell lymphoma, extranodal NK/Tcell lymphoma, transformed mycosis fungoides, hepatosplenic Tcell lymphoma
- •5. Failed at least 1 prior therapy (but no upper limit of prior regimens)
- •6. Adequate haematopoietic reserve (Hb = 9 g/dl, neutrophils =1.0x10(9)/l and platelets =100x10(9)/l or =75x10(9)/l if marrow involvement documented)
- •7. Adequate liver function (bilirubin =1.5 x upper limit of normal (ULN) (unless due to Gilbert’s syndrome), AST / ALT =2x ULN)
- •8. Adequate renal function (creatinine clearance = 20ml/min as assessed by Cockcroft and Gault calculation)
- •9. Serum potassium = 3.8 mmol/l, calcium = 2.2 mmol/l and magnesium = LLN prior to trial entry (supplements permitted)
- •10. CT measurable disease with at least 1 lesion having short axis >1.5 cm or splenomegaly >14 cm in craniocaudal
- •length attributable to relapsed lymphoma
- •11. Ability to give informed consent
- •*For all relapsed patients, relapse must be confirmed by tissue biopsy (or bone marrow trephine if no other tissue available). For refractory patients, a biopsy must have been obtained within the last 6 months and preferably to confirm refractory disease. In rare cases (such as when re-biopsy is not possible), the initial diagnostic biopsy may be accepted, provided that the patient has been reviewed at the local MDT who agreed that the presentation is consistent with relapsed/refractory T cell lymphoma, and this has been documented.
- •Previous inclusion criteria:
- •1. Age = 16 years of age
- •2. Life expectancy > 12 weeks
- •3. ECOG performance status = 2
- •4. Relapsed or refractory* peripheral Tcell lymphoma including the following histologies: peripheral Tcelllymphoma not otherwise specified, angioimmunoblastic Tcell lymphoma, anaplastic large cell lymphoma, enteropathy associated Tcell lymphoma, extranodal NK/Tcell lymphoma, transformed mycosis fungoides, hepatosplenic Tcell lymphoma
- •5. Failed at least 1 prior therapy (but no upper limit of prior regimens)
- •6. Adequate haematopoietic reserve (Hb = 9g/dl, neutrophils = 1.0x109/l and platelets = 100x109/l or = 75x109/l if marrow involvement documented)
- •7. Adequate liver function (bilirubin = 1.5 x ULN, AST / ALT = 2x ULN)
- •8. Adequate renal function (creatinine clearance = 20ml/min as assessed by Cockcroft and Gault calculation)
- •9. Serum potassium = 4.0 mmol/l, calcium = 2.2 mmol/l and magnesium = 0.85 mmol/l prior to trial entry
- •10. CT measurable disease with at least 1 lesion having short axis > 1.5cm or splenomegaly > 14cm in craniocaudal
- •length attributable to relapsed lymphoma
- •11. Ability to give informed consent
- •* For all relapsed patients, relapse must be confirmed by tissue biopsy (or bone marrow trephine if no other tissue available). For refr
排除标准
- •Current exclusion criteria as of 11/06/2018:
- •1. Persistent treatment related toxicities of CTCAE v4.0 grade = 2
- •2. Previous treatment with histone deactylase inhibitor or proteasome inhibitor
- •3. Need for any other concurrent anticancer drug (apart from corticosteroids at a dose equivalent to prednisolone =7.5mg daily). A steroid prephase may be used but should be stopped by the first day of cycle 1.
- •4. Concurrent medical illness deemed by the investigator as uncontrolled and/or clinically significant
- •5. Coexisting active infection requiring parenteral antibiotics
- •6. Patients unable to swallow oral medication
- •7. Active infection with HIV, hepatitis B or hepatitis C
- •8. Radiotherapy* (except for palliative reasons), endocrine therapy, immunotherapy or use of other investigationalagents within 28 days prior to trial entry (or a longer period depending on the defined characteristics of the agents used, please contact the trials office for confirmation). *Limited field radiotherapy to an isolated lesion in bone or soft tissue must be completed 2 weeks prior to trial entry
- •9. Major surgery within 4 weeks of trial entry
- •10. Patients with proven CNS involvement
- •11. QTc interval of >450ms or patients taking medications that significantly prolong the QT interval
- •12. Clinically significant cardiac disease = NYHA Class III, symptomatic ischaemia, conduction abnormalities uncontrolled by conventional intervention or myocardial infarction within 6 months of trial entry
- •13. Pregnant and lactating patients (patients of childbearing potential must have a negative pregnancy test prior to study entry and within 7 days prior to the start of treatment. Postmenopausal females (> 45 years old and without menstruation for > 1 year) and surgically sterilised females are exempt from a pregnancy test)
- •14. Patients and partners of childbearing potential not willing to use effective contraception during and for 3 months after therapy
- •15. Concurrent Pulmonary Hypertension
- •16. Left Ventricular Ejection Fraction (LVEF) of<40%
- •17. Patients taking any inhibitors or strong inducers of CYP3A4, with the exception of dexamethasone.
- •18. Previous systemic malignancy within the last 3 years unless treated with curative intent with no sign of recurrence. Other exceptions include non-melanotic skin cancer or carcinoma in-situ of the uterine cervix
- •Previous exclusion criteria:
- •1. Persistent treatment related toxicities of CTCAE v4.0 grade = 2
- •2. Previous treatment with histone deactylase inhibitor or proteasome inhibitor
- •3. Need for any other concurrent anticancer drug (apart from corticosteroids at a dose equivalent to prednisolone =7.5mg daily). A steroid prephase may be used but should be stopped by the first day of cycle 1.
- •4. Concurrent medical illness deemed by the investigator as uncontrolled and/or clinically significant
- •5. Coexisting active infection requiring parenteral antibiotics
- •6. Patients unable to swallow oral medication
- •7. Active infection with HIV, hepatitis B or hepatitis C
- •8. Radiotherapy* (except for palliative reasons
研究者
相似试验
进行中（未招募）
1 期
A phase I/II study to find the safe dose of the combination of romidepsin and carfilzomib (phase I) in patients with relapsed or refractory T-Cell lymphoma. The phase II part of the study will look at the activity of the combination.Peripheral T-cell LymphomaMedDRA version: 20.0Level: PTClassification code 10034626Term: Peripheral T-cell lymphoma unspecified refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10034625Term: Peripheral T-cell lymphoma unspecified recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001879-20-GBniversity of Birmingham57
撤回
不适用
A phase I study to determine the maximum tolerable dose (MTD) of weekly carboplatin with the Wee1 inhibitor AZD1775 in patients with p53 mutated solid tumors.NL-OMON45937Antoni van Leeuwenhoek Ziekenhuis30
已完成
1 期
A Phase I Study of LBH589 in Children With Refractory Solid and Central Nervous System (CNS) TumoursACTRN12609000978268Australian and New Zealand Children's Haematology and Oncology Group (ANZCHOG)52
已完成
1 期
Capecitabine and oral cyclophosphamide - a novel oral treatment combination for advanced cancerAdvanced CancerCancer -ACTRN12605000375651Dr Michael Findlay40
进行中（未招募）
不适用
A PHASE I-II STUDY EVALUATING THE MAXIMUM TOLERATED DOSE,DOSIMETRY, SAFETY, AND EFFICACY OF ULTRATRACE™ IOBENGUANE I 131 INPATIENTS WITH MALIGNANT PHEOCHROMOCYTOMA/PARAGANGLIOMAEUCTR2007-002211-11-GBMolecular Insight Pharmaceuticals, Inc62